Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer

Table 4 Results of Cox univariate analyses

Characteristic	Progression-free survival			Overall survival
	Hazard ratio	95%CI	P-value	Hazard ratio	95%CI	P-value
Age, yr
Continuous	0.990	0.968; 1.012	0.36	0.988	0.968; 1.007	0.22
Gender
Female	1			1
Male	1.003	0.673; 1.497	0.99	0.992	0.655; 1.502	0.97
Who performance status
0	1			1
1	1.588	0.832; 3.034	0.16	2.157	1.086; 4.284	0.03
2	2.165	0.925; 5.068	0.08	4.865	2.061; 11.49	< 0.001
Primary location
Right colon	1			1
Left colon	0.953	0.589; 1.541	0.84	0.919	0.556; 1.520	0.74
Rectum	1.054	0.634; 1.752	0.84	0.879	0.525; 1.470	0.62
Initial cancer status
Synchronous	1			1
Metachronous	0.862	0.554; 1.340	0.51	0.887	0.562; 1.398	0.60
Number of metastastatic sites
1	1			1
2	1.040	0.640; 1.692	0.87	1.085	0.654; 1.798	0.75
≥ 3	1.347	0.796; 2.279	0.27	1.449	0.847; 2.476	0.18
Surgery of primary
No	1			1
Yes	0.947	0.622; 1.442	0.80	0.893	0.575; 1.387	0.61
Surgery of metastases
No	1			1
Yes	0.562	0.342; 0.924	0.02	0.754	0.458; 1.241	0.27
Line of therapy
Second	1			1
Third	0.878	0.421; 1.832	0.73	0.944	0.441; 2.020	0.88
More	1.340	0.655; 2.740	0.42	1.155	0.548; 2.432	0.71
Treatment
FOLFIRI3	1			1
FOLFIRI3 + Bevacizumab	0.547	0.304; 0.983	0.04	0.647	0.354; 1.180	0.16
FOLFIRI3 + Aflibercept	0.354	0.181; 0.694	0.002	0.367	0.184; 0.729	0.004
Irinotecan chemotherapy-naive
No	1			1
Yes	0.979	0.548; 1.748	0.94	1.114	0.609; 2.038	0.73
RAS/BRAF mutation status
Not mutated	1			1
Mutated	1.045	0.679; 1.611	0.84	1.232	0.784; 1.935	0.37